Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.
Maestro Pro and Maestro Edge are the world’s most advanced MEA platforms. When combined with modern cell culture technologies, Axion’s platform allows scientists to model human heartbeats and brain activity in a dish. Axion’s products are used by pharmaceutical and biotech companies, governmental agencies, and universities for drug safety, drug discovery, and disease modeling assays.
"Axion’s product portfolio represents very high-quality laboratory instrumentation, consumables, and software for the in vitro life science market. With the vast interest in stem cell-based assays in Japan, the Axion brand is a great fit with our strategy to focus on in vitro cellular models," said Chikafumi Yokoyama, CEO REPROCELL Inc.
"We are very excited to partner with REPROCELL as they have a long history of providing quality sales, service, and support to customers in the cell-based assay market," noted Tom O’Brien, President and CEO, Axion BioSystems. "This partnership with REPROCELL will allow us to accelerate sales of our current, and soon-to-be released products, due to their extensive relationships with the life science customer base in Japan."
About Axion BioSystems, Inc.
Axion is a life science company located in Atlanta, GA, has developed the industry’s first high-throughput MEA product line. MEAs are used for the in vitro investigation of networks of electrically active cells; neurons, cardiac cells, muscle cells etc. When combined with modern cell culture technologies, Axion’s platform allows scientists to model human heart and brain activity in a dish. Axion’s products are used by pharmaceutical and biotech companies, governmental agencies, and universities for disease modeling, drug safety, and drug discovery assays.
REPROCELL is a global contract research organization with laboratories across Japan, Europe, US and now India. They specialize in a range of services and products focused around translational medicine and stem cell research. Their most recent joint venture with GenAhead Bio has allowed the company to offer the fastest gene editing service on the market – CRISPR-SNIPER*, which uses an advanced screening system to determine if a genetic modification is feasible in just two weeks.
For Press Enquiries: Zara Puckrin, Marketing Manager, email@example.com